Returning to the original intention of treating diseases and saving lives, People's Daily Review: Strictly crack down on medical corruption, over a hundred hospital leaders have been investigated for corruption | in the field |
The anti-corruption efforts in the pharmaceutical industry have been deepened, and multiple hospital leaders have fallen behind in response.
According to media reports, as of August 6th, the number of hospital party secretaries and deans who have been publicly reported as being investigated nationwide has reached 168. Due to statistical limitations, this number may actually be even higher. All kinds of signs indicate that the anti-corruption efforts in the medical field are unprecedented in strength and breadth, and are real.
In fact, the investigation of the hospital party secretary and director does not seem sudden. According to incomplete statistics from the People's Daily Health Client, 46 hospital party secretaries and deans were investigated before April this year, and dozens of hospitals or designated retail pharmacies were fined for illegal use of medical insurance funds. In May, the National Health Commission and 14 other departments jointly issued a notice on the key points for correcting unhealthy practices in the field of pharmaceutical procurement and sales and medical services in 2023, requiring the improvement of the professional ethics governance system and focusing on addressing prominent corruption issues in the pharmaceutical industry. This is the first deployment of rectification work in accordance with the adjustment of the composition departments and relevant functions of the State Council, and the adjustment of member units of the inter ministerial joint working mechanism to correct misconduct in the field of pharmaceutical procurement and sales and medical services.
In addition to unprecedented efforts, this anti-corruption storm in the medical field has also directly hit the key and difficult points. According to China Newsweek, the corruption problem in China's medical system mainly focuses on drug distribution, equipment procurement, consumables supply, engineering construction, and other aspects. The extra costs paid by hospitals are passed on to patients and finance. Previously, the website of the Central Commission for Discipline Inspection and the National Supervisory Commission disclosed a case: a medical device linear accelerator imported for 15 million yuan was purchased by a hospital for 35.2 million yuan, and the rebate in between was actually eaten by the hospital director for 16 million yuan. Key figures in medical institutions have become the focus of this round of medical anti-corruption efforts.
In addition to targeting key areas, this corruption in the medical field is more focused on addressing the root cause. On July 28th, the Central Commission for Discipline Inspection and the National Supervisory Commission held a mobilization meeting, deploying disciplinary inspection and supervision agencies to cooperate in carrying out centralized rectification of corruption in the national pharmaceutical industry. The mobilization meeting clearly emphasized the need to deepen the systematic governance of the pharmaceutical industry across all fields, chains, and coverage.
If the "Three Comprehensives" demonstrate the determination of source governance, then in specific governance, emphasis is placed on "increasing disciplinary and law enforcement efforts, closely monitoring leading cadres and key personnel, and adhering to the joint investigation of bribery and bribery", which reflects precise governance. It can not only concentrate efforts to investigate and deal with a batch of corruption cases in the pharmaceutical field, form a deterrent effect, but also provide experience for anti-corruption in the pharmaceutical field through governance practice.
Faced with the current anti-corruption storm in the medical field, netizens exclaimed that it is very satisfying. In fact, the country has been vigorously promoting anti-corruption in the pharmaceutical industry, and the reason why it has received much attention this time is mainly due to two reasons. One is that comprehensive, full chain, and full coverage governance has eliminated a group of "medical pests", allowing patients to obtain more tangible benefits; Another is to focus on the construction of a corruption prevention system and effectively eradicate the soil and conditions for the breeding of corruption.
Obviously, plugging loopholes is essential to effectively prevent loopholes from being exploited; Constraining power is the key to preventing kickbacks. At the same time, increasing supervision and achieving more efficient supervision are necessary to gradually reduce corruption in the pharmaceutical industry.
Corruption never follows the rules of prohibition, and the system is the fundamental solution. The governance of corruption in the pharmaceutical industry has already begun to take effect, and this will not be the end point. Step by step, step by step, and achieve a comprehensive approach to treating both symptoms and root causes, in order to rectify the root cause, return to the original intention of treating diseases and saving people, and make patients feel more fulfilled.
